Advanstar reports first-half revenues up 13%

Share this article:
Advanstar reported first-half revenues up 13% year-on-year, from $146 million to $165 million--though its life sciences division was nearly flat for Q2. Revenues from Advanstar life sciences properties rose by 3% for the period, as overall revenues rose 6%, largely on a 24% jump in the firm's power sports division. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.